Something profoundly discomfiting for the global energy sector recently happened in the Netherlands. The global oil sector might think it is pulling out all the stops to keep multiple plates spinning (keeping a predominantly oil-reliant world still energised and moving, while investing in and developing alternative sources of energy, and cutting carbon emissions in line with the target of carbon net-zero by 2050), but influential voices think otherwise. On Wednesday, a Dutch district court in the Hague ruled in favour of a suit brought in a class action led by Milieudefensie, the Dutch wing of Friends of the Earth, that Royal Dutch Shell was in breach of its duty to meet global temperature targets and ordered the company to cut its carbon emissions by 45% by 2030 compared with 2019 levels.

 

The company’s strategic plan seemed clear and, on the face of it ambitious, not only to be carbon net-zero, but for the products it sells to have no CO2 emissions at all by 2050: its pathway published in February laid out product carbon reductions of 6-8% by 2023, 20% by 2030, 45% by 2035 and 100% by 2050. However, as reported in The Guardian, arguing under Dutch law and European Human Rights Convention articles covering activities which endanger life that, while the company had done nothing illegal, the court ruled that the company’s “policy intentions and ambitions for the Shell group largely amount to rather intangible, undefined and non-binding plans for the long-term”. Further, it found those plans were “dependent on the pace at which global society moves towards the climate goals of the Paris agreement” and that the “emissions reduction targets for 2030 are lacking completely”. In other words, the court effectively accused the company of hiding behind the Paris Climate Accord timetable, whose limits and timetable are themselves legally binding, to dawdle wilfully, to kick the can down the road.

 

Whether one agrees with the Paris Climate Accord or not is irrelevant: it’s there, in law, and many signatories including the UK have already enacted national legislation with carbon reduction milestones to be achieved for the overall obligation to be met by 2050. However, as we have discussed in these columns before, there are profound disagreements behind what is superficially a simple and clear objective. What is the definition of ‘net zero’? What is an acceptable way for it to be achieved? What are acceptable alternatives to carbon? Some baulk at the concept of net-zero, as to them nothing less than the total elimination of carbon is acceptable. The arguments go on. And now, a lower court rules that notwithstanding Shell’s target not only meets but possibly exceeds the internationally agreed net-zero by 2050, it’s not good enough.

 

In many ways this case encapsulates the accelerating shambles created by the political tensions arising out of the climate agenda with all its competing and vocal forces. But it is against this backdrop that major global businesses, ones such as Shell which currently make the world go round, must make detailed long-term calculations involving complex planning and implementation and the investment of billions, if not in aggregate trillions of dollars.

 

Does this case set a precedent? Is every company’s climate plan now to be scrutinised in court simply because protest groups disagree with it? The Shell board might well be entitled to say to the court in the Hague, “our plan is clear. It not only complies with meeting an international treaty, it may even exceed it; you might not agree with how we’re going about it but that’s only your opinion. Just who is running this company? Friends of the Earth? A local Dutch judge? Or us”. Shell will appeal.

The enduring war between Brussels and AstraZeneca

While on the subject of perverse behaviour potentially ending up in court, the EU is seeking multi-billion euro damages from AstraZeneca (based on a calculation of €10/dose/day shortfall against contract delivery by next month) for failing to honour its supply of Covid vaccines. Perverse because, amid all the blood clot hullaballoo earlier in the year and whether the AstraZeneca vaccine was safe and many EU leaders very publicly walked away from the vaccine, if not actually trashing its reputation in the process, what once seemed a pariah product on the Continent is now potentially worth billions of euros in damages for not enough being supplied.

Corporation Tax: global minimum rate talks begin

Finally, as we approach the G7 summit in Cornwall under UK chairmanship, alongside discussions about Belarus, Iran, China and Russia, the subject of Janet Yellen’s new minimum global rate of corporation tax will be aired. America’s opening gambit of 21% already seems moribund, with press reports indicating 15% as more likely. Low tax economies designed to attract inward investment, such as Ireland with a national tax rate of 12.5% and Singapore at 17% could have seen significant disinvestment as a result. The aim is to remove the ability of the big multinationals, and particularly Big Tech, operating in many tax jurisdictions simultaneously, to arbitrage the system to minimise their tax liabilities. While many key countries are on board with the idea, the hard bargaining with national interests at the forefront has only just begun. But over time we should get a better idea of which companies are most likely to be affected and by how much.

 

The Jupiter Merlin Portfolios are long-term investments; they are certainly not immune from market volatility, but they are expected to be less volatile over time, commensurate with the risk tolerance of each.  With liquidity uppermost in our mind, we seek to invest in funds run by experienced managers with a blend of styles but who share our core philosophy of trying to capture good performance in buoyant markets while minimising as far as possible the risk of losses in more challenging conditions.

Please note

Past performance is no guide to the future. Market and exchange rate movements can cause the value of an investment to fall as well as rise, and you may get back less than originally invested.  The views expressed are those of the authors at the time of writing are not necessarily those of Jupiter as a whole and may be subject to change.  This is particularly true during periods of rapidly changing market circumstances.

Fund specific risks

The NURS Key Investor Information Document, Supplementary Information Document and Scheme Particulars are available from Jupiter on request. The Jupiter Merlin Conservative Portfolio can invest more than 35% of its value in securities issued or guaranteed by an EEA state. The Jupiter Merlin Income, Jupiter Merlin Balanced and Jupiter Merlin Conservative Portfolios’ expenses are charged to capital, which can reduce the potential for capital growth

Important information

This document is for informational purposes only and is not investment advice. We recommend you discuss any investment decisions with a financial adviser, particularly if you are unsure whether an investment is suitable. Jupiter is unable to provide investment advice. For definitions please see the glossary at jupiteram.com. Every effort is made to ensure the accuracy of any information provided but no assurances or warranties are given. Company examples are for illustrative purposes only and not a recommendation to buy or sell. Jupiter Unit Trust Managers Limited (JUTM) and Jupiter Asset Management Limited (JAM), registered address: The Zig Zag Building, 70 Victoria Street, London, SW1E 6SQ are authorised and regulated by the Financial Conduct Authority. No part of this document may be reproduced in any manner without the prior permission of JUTM or JAM. 27595